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Abstract
Background: Although agmatine therapy in a mouse model of transient focal cerebral ischemia is highly
protective against neurological injury, the mechanisms underlying the protective effects of agmatine are not fully
elucidated. This study aimed to investigate the effects of agmatine on brain apoptosis, astrogliosis and edema in
the rats with transient cerebral ischemia.
Methods: Following surgical induction of middle cerebral artery occlusion (MCAO) for 90 min, agmatine (100 mg/kg,
i.p.) was injected 5 min after beginning of reperfusion and again once daily for the next 3 post-operative days. Four
days after reperfusion, both motor and proprioception functions were assessed and then all rats were sacrificed for
determination of brain infarct volume (2, 3, 5-triphenyltetrazolium chloride staining), apoptosis (TUNEL staining),
edema (both cerebral water content and amounts of aquaporin-4 positive cells), gliosis (glial fibrillary acidic protein
[GFAP]-positive cells), and neurotoxicity (inducible nitric oxide synthase [iNOS] expression).
Results: The results showed that agmatine treatment was found to accelerate recovery of motor (from 55 degrees
to 62 degrees) and proprioception (from 54% maximal possible effect to 10% maximal possible effect) deficits and
to prevent brain infarction (from 370 mm3 to 50 mm3), gliosis (from 80 GFAP-positive cells to 30 GFAP-positive
cells), edema (cerebral water contents decreased from 82.5% to 79.4%; AQP4 positive cells decreased from 140 to
84 per section), apoptosis (neuronal apoptotic cells decreased from 100 to 20 per section), and neurotoxicity (iNOS
expression cells decreased from 64 to 7 per section) during MCAO ischemic injury in rats.
Conclusions: The data suggest that agmatine may improve outcomes of transient cerebral ischemia in rats by
reducing brain apoptosis, astrogliosis and edema.
Background
It is believed that aquaporin-4 (AQP4) is abundantly
expressed by astrocytes lining the ependymal and pial
surface that are in contact with cerebrospinal fluid in
the cerebroventricular system and subarachnoid space
[1]. Highly polarized AQP4 expression is also found in
astrocytic foot process near or in direct contact with
blood vessels [2]. In fact, AQP4, functions as an efficient
water-selective transporting protein in the central ner-
vous system [3]. Mice deficient in AQP4 have much bet-
ter survival than wild-type mice in a model of brain
edema caused by acute water intoxication [4]. In
another model of brain edema, focal ischemic stroke
produced by middle cerebral artery occlusion (MCAO),
AQP4-deficient mcie have improved neurological output
[4]. These results suggest that AQP4 may play an
important role in cerebral ischemia-induced brain
edema in the mouse [5]. Inducible nitric oxide synthase
(iNOS) has also been shown to participate in the neuro-
nal damage of focal cerebral ischemia [6,7].
Agmatine, formed by the decarboxylation of L-arginine
by arginine decarboxylase, is synthesized in the mamma-
lian brain [8]. Several recent evidence have accumulated
to indicate that agmatine has neuroprotective effects in
many disease models [9-21]. It was shown that agmatine
therapy in rodent model of transient focal cerebral ische-
mia was highly protective against neurological injury
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[15,21]. A more recent report showed agmatine treat-
ment decreased the AQP4 expression in ischemic mice
[22]. However, the mechanisms underlying the neuropro-
tective effects of agmatine remain unclear.
The aims of the present study was to assess the effects
of systemic delivery of agmatine on the MCAO-induced
motor and proprioceptive dysfunction 4 days after
MCAO to determine whether agmatine therapy would
produce beneficial effects on histochemical markers of
apoptosis, astrogliosis and edema.
Methods
Reagents
Agmatine was used in its sulfate salt form, purchased
from Sigma co. Ltd (MO, USA) and dissolved in 0.9%
saline for administration.
Animals and stroke model
Adult male Sprague-Dawley rats (weight, 253 ± 10 g)
were housed under controlled environmental conditions
with ambient temperature of 22 ± 1°C, relative humidity
of 65% and 12-h light/dark cycle, with free access to
food and water. Brain focal ischemia was induced by
MCAO in rats by intraluminal filament, using the rela-
tively non-invasive technique previously described by
Belayev et al. [23]. Briefly, rats were anesthetized with
sodium pentobarbital (25 mg/kg, i.p.), ketamine (44 mg/
kg, i.m.), atropine (0.02633 mg/kg, i.m.), and xylazine
(6.77 mg/kg, i.m.). Body temperature was measured with
a rectal probe and was kept at 37°C during the surgical
procedure with a heating pad. Under an operating
microscope, the external and internal right carotid
arteries were exposed through a neck incision. The
external carotid artery was cut approximately 3 mm
above the common carotid artery bifurcation and a silk
suture was tied loosely around the external carotid
stump. A silicone-coated nylon filament (diameter: 0.37
mm, Doccal Corporation, Redlands, CA, USA) was then
inserted into the external carotid artery and gently
advanced into the internal carotid artery, approximately
18 mm from the carotid bifurcation, until mild resis-
tance was felt, thereby indicating occlusion of the origin
of the middle cerebral artery in the Willis circle. The
suture was tightened around the intraluminal filament
to prevent bleeding. To allow reperfusion, the nylon fila-
ment was withdrawn 90 minutes after MCAO. The ani-
mals were allowed to awaken and were kept in their
cages with free access to food and water.
Experimental design
Ninty-six Animals were randomly assigned to sham-
operated group (n = 32), MCAO rats treated with saline
(1 ml/kg, i.p.) (n = 32), or MCAO rats treated with
agmatine (n = 32). All tests were run blinded, and the
animal codes were revealed only at the end of the beha-
vioral and histological analyses. Agmatine (Sigma
Chemical Co., St. Louis, Mo, USA) was injected (100
mg/kg, i.p.) 5 min after beginning of reperfusion and
again once daily for the next 3 post-operative days [21].
All the experimental procedures were carried out in
accordance with the National Institutes of Health
Guidelines and were approved by the Chi Mei Medical
Center Animal Care and Use Committee to minimize
the discomfort to the animals during surgery and in the
recovery period.
In the rat model, AQP4 mRNA was increased 3 days
after ischemia [24]. In the following experiments, all the
assessments except behavioral tests were conducted
4 days after MCAO (Table 1).
Motor function test
The inclined plane was used to measure limb strength.
Animals were placed, facing right and then left, perpen-
dicular to the slope of a 20 × 20-cm ruffer ribbed sur-
face of an inclined plane starting at an angle of 55°
[25,26]. The angle was increased or decreased in 5°
increments to determine the maximal angle an animal
could hold to the plane. Data for each day were the
means of left and right side maximal angle. Measure-
ments of motor deficits were conducted daily but only
the 4th day values were presented.
Cerebral infarction assessment
Rats were with deep anesthesia and were transcardially
perfused with heparinized 0.05-mol/L phosphate-buf-
fered saline (PBS) followed by ice-cold 15% sucrose in
PBS. The brains were rapidly removed and frozen in
liquid nitrogen and then sectioned for immunohisto-
chemistry. Eight serial sections from each brain were cut
at 2-mm intervals from the frontal pole using a rat brain
matrix (Harvard Apparatus, Holliston, MA, USA). To
measure ischemic change, brain slices were stained in a
solution containing 2% 2,3,5-triphenyltetrazolium chlor-
ide (TTC) in saline, at 37°C. The brain sections stained
with TTC were performed in all the three groups. Each
group contained 6 animals. After 10 min incubation, the
slices were transferred to 5% neutral buffered formaline
and stored at 4°C prior to analysis. Infarct volume (mm3),
as revealed by negative TTC stains indicating dehydro-
genase-dificient tissue, was measured in each slice and
summed using computerized planimetry (PC-based
image tools software). The volume of infarction was cal-
culated as 2 mm (thickness of the slice) × (sum of the
infarction area in all brain slices [mm2]) [27].
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Brain water contents
Four days after MCAO, rats were killed and brains were
removed. The pons and olfactory bulb were removed
and the brains were weighted to obtain their wet weight
(ww). Thereafter brains were dried at 110°C for 24 h for
determing their dry weight (dw). Brain water content
was calculated by using the following formula: (ww-dw)/
ww × 100 [28] as used as an index for brain edema.
Immunohistological determination
Adjacent 50-μm sections corresponding to coronal
coordinates 0.2 mm to 0.7 mm anterior to the bregma
were incubated in 2 mol/L HCL for 30 min, rinsed in
0.1 mol/L boric acid (pH 8.5) for 3 min at room tem-
perature and then incubated with primary antibodies in
PBS containing 0.5% normal bovine serum at 4°C over-
night. After being washed in PBS, the sections were
incubated with secondary antibodies for 1 h at room
temperature. The following primary antibodies were
used in this study: inducible nitric oxide synthase
(iNOS; 1:200 BD bioscience), anti-neuronal-specific
nuclear protein (Neu N, 1:200 Roche Diagnostics);
GFAP (1:400 Abcam) or AQP4 (1:100 Chemicon) and
then detected with Alexa-Fluor®, 568 grat anti-mouse
(IgG) antibody. The sections were examined using an
Olympus B × 51 microscope. The stained cells in
ischemic ortex (penumbra) were calculated in 3 coronal
sections from each rat and summed and expressed as
the mean number per mm2. The numbers of labeled
cells were counted from the equivalent field for 3 differ-
ent groups of rats. For negative coronal sections, all
procedures were performed in the same manner with-
out the primary antibodies.
TUNEL assay
Brain tissues were embedded in paraffin and then sec-
tioned for the TUNEL assay. TUNEL assay was used for
assessment of apoptosis. The color was developed using
3,3-diamino-benzidine tetrachloride (DAB). The sections
were xylene- and ethanol-treated for paraffin removal
and for dehydration. They were then washed with PBS
and incubated in 3% H2O2 solution for 20 min. The sec-
tions were treated with 5 μg/ml proteinase k for 2 min
at room temperature, and re-washed with PBS (0.1 M,
pH7.4, PBS). The sections were then treated with a
TNLE reaction mixture (nucleotide Rochel Mannheim,
Germany) at 37°C for 1 h, and then the sections were
washed with distilled water (D/W). They were then re-
incubated in an-fluorescein antibody-conjugated with
horseradish peroxidase at room temperature for 30 min,
re-wash, and then visualized using the avidin-biotin-
peroxidase complex (ABC) technique and 0.05% 3,3-
diaminobenzidine (DAB, Sigma) as a chromogen. The
numbers of TUNEL positive cells were counted by a
pathologist in 30 fields/sections (×200 magnification).
The blinding was performed for the pathology grading
of the results.
Proprioception
Proprioception evaluation was based on the resting, pos-
ture, and postural reactions ("tactile placing” and “hop-
ping”) [29]. The functional deficit was graded as 3
(normal or 0% maximal possible effect [MPE], 2 (slightly
impaired), 1 (severely impaired), and 0 (completely or
100% MPE) [30]. This test was performed by lifting the
front half of the animal off the ground and lifting one
hind limb at a time off the ground so that the animal
was standing on just one limb. Then, the animal was
moved laterally, which normally evoked a prompt hop-
ping response with the weight- bearing limb in the
direction of movement to prevent the animal from fall-
ing. A predominant motor block would cause a prompt
but weaker-than-normal response. Conversely, a predo-
minantly proprioceptive block causes a delayed hopping
followed by greater lateral hops to prevent the animal
from falling. In the case of full blockade, there would be
no hopping maneuvers [31].
Statistics
One way analysis of variance (ANOVA) test was used
for comparing the differences between the groups.
When the ANOVA showed significant differences, the
post hoc multiple comparison test (Tukey) was applied.
The neurological scores were compared by Kruskal-
Wallis one way ANOVA followed by multiple compari-
son procedures by Dunn’s method. The data were
expressed as means ± standard deviation (S.D.), and P <
0.05 was accepted as statistical significant.
Table 1 Experimental plan
















1. sham operated rats n = 8 n = 8 n = 8 n = 8 n = 8 n = 8 n = 8 n = 8
2. (MCAO+saline) rats n = 8 n = 8 n = 8 n = 8 n = 8 n = 8 n = 8 n = 8
3. (MCAO+Agmatine)
rats
n = 8 n = 8 n =8 n =8 n =8 n = 8 n = 8 n = 8
n, numbers of animals used. All measurements were performed 4 days after MCAO or sham operation.
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Results
Agmatine attenuates MCAO-induced motor deficits
Maximal grip angle 1-4 days after MCAO injury was
significantly decreased for MCAO-injured animals trea-
ted with an i.p. dose of normal saline compared with
MCAO sham controls (Fig. 1). The maximal grip angle
2-4 days after MCAO injury was significantly increased
for MCAO-injured animals treated with an i.p. dose of
agmatine compared with vehicle controls (62 degrees vs
54 degrees; Fig. 1).
Agmatine attenuates MCAO-induced proprioception
blockade
The percentage of MPE or proprioception blockade 1-4
days after MCAO injury was significantly increased for
MCAO-injured animals treated with an i.p. dose of nor-
mal saline compared with MCAO sham controls
(Fig. 2). The MCAO-induced proprioception blockade
2-4 days after MCAO injury was significantly reversed
by an i.p. dose of agmatine (100 mg/kg; p < 0.05) (10%
MPE vs 54% MPE; Fig. 2).
Agmatine attenuates MCAO-induced cerebral infarction
volume
The cerebral infarction volume 4 days after MCAO
injury was significantly increased for MCAO-injured
animals treated with an i.p. dose of normal saline com-
pared with MCAO sham controls (Fig. 3). The infarc-
tion volume 4 days after MCAO injury was significantly
reduced for MCAO-injured animals treated with an i.p.
dose of agmatine compared with vehicle controls
(370 mm3 vs 50 mm3) (Fig. 3).
Agmatine attenuates MCAO-induced cerebral edema
The brain water content 4 days after MCAO injury was
significantly increased for MCAO-injured animals trea-
ted with an i.p. dose of normal saline compared with
MCAO sham controls (Fig. 4). The cerebral water con-
tent 4 days after MCAO injury was significantly
decreased for MCAO-injured animals treated with an
i.p. dose of agmatine compared with vehicle controls
(82.5% vs 79.4%; Fig. 4).
Agmatine attenuates MCAO-induced cerebral gliosis
The numbers of GFAP-positive cells 4 days after MCAO
injury was significantly increased for MCAO-injured
animals treated with an i.p. dose of normal saline com-
pared with MCAO sham controls (Fig. 5). The increased
numbers of GFAP-positive cells 4 days after MCAO
injury was significantly reversed for MCAO-injured ani-
mals treated with an i.p. dose of agmatine compared
with vehicle controls (100 GFAP-positive cells vs
20 GFAP-positive cells per section; Fig. 5).
Agmatine attenuates MCAO-induced overexpression of
iNOS
The numbers of iNOS-positive cells 4 days after MCAO
injury was significantly increased for MCAO-injured
animals treated with an i.p. dose of normal saline
Figure 1 Daily maximal angle animals could cling to an
inclined plane for 8 sham-operated rats (□), 8 vehicle-treated
MCAO-injured rats (▨), and 8 agmatine-treated MCAO-injured
rats (▩). *Maximal grip angle 2-4 days after MCAO was significantly
(P < 0.05) decreased for MCAO-injured animals treated with an i.v.
dose of normal saline (1 mL/kg) compared with sham controls.
†Maximal grip angle 2-4 days after MCAO injury was significantly
(P < 0.05) increased for MCAO-injured animals treated with an i.v.
dose of agmatine (100 mg/kg) compared with vehicle controls.
Figure 2 Daily percentage of maximal possible effect (%MPE)
of proprioception blockade by 8 sham-operated rats (□), 8
vehicle-treated MCAO-injured rats (▨), and 8 agmatine-treated
MCAO-injured rats (▩). *The percent of MPE 2-4 days after MCAO
injury was significantly (P < 0.05) increased for MCAO-injured
animals treated with an i.v. dose of normal saline (1 mL/kg)
compared with MCAO sham controls. †The percentage of MPE 2-4
days after MCAO injury was significantly decreased for MCAO-
injured animals treated with an i.v. dose of agmatine (100 mg/kg)
compared with vehicle controls.
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compared with MCAO sham controls (Fig. 6). The
increased numbers of iNOS-positive cells 4 days after
MCAO injury was significantly decreased for MCAO-
injured animals treated with an i.p. dose of agmatine
compared with vehicle controls (64 iNOS-positive cells
vs 7 iNOS-positive cells per section; Fig. 6).
Agmatine attenuates MCAO-induced neuronal apoptosis
The numbers of neuronal apoptosis cells 4 days after
MCAO injury was significantly decreased for MCAO-
injured animals treated with an i.p. dose of normal
saline compared with MCAO sham controls (Fig. 7).
The decreased numbers of neuronal apoptosis cells
4 days after MCAO injury was significantly decreased
for MCAO-injured animals treated with an i.p. dose of
agmatine compared with vehicle controls (100 vs
20 cells per section; Fig. 7).
Agmatine attenuates MCAO-induced overexpression of
AQP4
The numbers of cerebral AQP4-positive cells 4 days
after MCAO injury was significantly increased for
Figure 3 Infarction volume (B) by MCAO in rats (n = 8 in each group of different treatments). *The infarction volume 4 days after MCAO
injury was significantly (P < 0.05) increased for MCAO-injured animals treated with an i.v. dose of normal saline (1 mL/kg) compared with MCAO
sham controls. †The infarction volume 4 days after MCAO-injury was significantly decreased for MCAO-injured animals treated with an i.v. dose of
agmatine (100 mg/kg) compared with vehicle controls. The photomicrograph (A) illustrates the infarction for a sham-operated rat, a MCAO rat
treated with normal saline, and a MCAO rat treated with agmatine. Triphenyltetrazolium chloride staining shows severe infarctions characterized
by pale TTC stains (whitish color) in the cortex and striatum on all brain sections examined.
Figure 4 Cerebral edema by MCAO in rats (n = 8 in each
group of different treatments). *The brain water content 4 days
after MCAO injury was significantly (P < 0.05) increased for MCAO-
injured animals treated with an i.v. dose of normal saline (1 mL/kg)
compared with MCAO sham controls. †The cerebral water content 4
days after MCAO injury was significantly decreased for MCAO-
injured animals treated with an i.v. dose of agmatine (100 mg/kg)
compared with vehicle controls.
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MCAO-injured animals treated with an i.p. dose of nor-
mal saline compared with MCAO sham controls (Fig.
8). The increased numbers of cerebral AQP4-positive
cells 4 days after MCAO injury was significantly
decreased for MCAO-injured animals treated with an i.
p. dose of agmatine compared with vehicle controls (140
vs 84 AQP4-positive cells per section; Fig. 8).
Discussion
Agmatine’s effect on reducing the edema formation after
cerebral ischemia was already been reported but the
results suggesting the agmatine’s therapeutic potential
was convincing [15,21,22]. Our results demonstrate that
agmatine therapy reduces neuronal apoptosis, gliosis,
and edema in an animal model of stroke followed by
reperfusion. In particular the MCAO-induced overex-
pression of cerebral AQP4 can be greatly reduced by
agmatine therapy, suggesting that the enhanced water
movement associated with the pathophysiology of cere-
bral edema after transient cerebral ischemia is attenu-
ated by agmatine. It is believed that AQP4 is abundantly
expressed by astrocytes lining the ependymal and pial
surface that are in contact with cerebrospinal fluid in
the cerebroventricular system and subarachnoid space
[1]. Highly polarized AQP4 expression is also found in
astrocytic foot process near or in direct contact with
blood vessels [2]. As demonstrated in the current
results, the MCAO-induced overexpression of cerebral
AQP4 can be attenuated following systemic delivery of
agmatine in rats. Moreover agmatine treatment
decreased the AQP4 expression in ischemic mice [22].
Evidence indicates that AQP4 functions as an efficient
water-selective transporting protein in the central ner-
vous system [3]. Mice deficient in AQP4 have much bet-
ter survival than wild-type mice in a model of brain
edema caused by acute water intoxication [4]. In
another model of brain edema, focal ischemic stroke
produced by MACO, AQP4-deficient mice have
improved neurological output [4].
In the present study, histoimmunological evaluation
reveals that, at 4 days after MCAO, gliosis (evidenced by
increased numbers of both GFAP-positive and AQP4-
positive cells) and neuronal apoptosis (evidenced by
increased numbers of NeuN and TUNEL double posi-
tive cells) in the ischemic cortex, can be greatly reduced
by agmatine therapy. The reduction of both gliosis and
neuronal apoptosis in agmatine-treated ischemic animal
is paralled by the reduced infarct volume and near nor-
mal motor and proprioceptive function. Thus, it appears
that agmatine may protect against the delayed infarct
Figure 5 Gliosis by MCAO in rats (n = 8 in each group of different treatments). *The number of GFAP-positive cells (B) 4 days after MCAO
injury was significantly (P < 0.05) increased for MCAO-injured animals treated with an i.v. dose of normal saline (1 ml/kg) compared with MCAO
sham controls. †The increased number of GFAP-positive cells 4 days after MCAO injury was significantly decreased for MCAO-injured animals
treated with an i.v. dose of agmatine (100 mg/kg) compared with vehicle controls. The photomicrograph (A) illustrates a typical example for a
sham-operated control, a vehicle-treated MCAO rat, and an agmatine-treated MCAO rat.
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expansion caused by activated astrocytes during transi-
ent cerebral ischemia. Astrocytes are believed to be
responsible for most glutamate uptake in synaptic areas
and consequently are the major regulators of glutamate
homeostasis [32]. Microglia in turn may secrete cyto-
kines, which can impair glutamate uptake. Finally, oligo-
dendrocytes, the myelinating cells of the central nervous
system, are very sensitive to excessive glutamate signal-
ing, which can lead to the apoptosis or necrosis of these
cells [32]. Agmatine, an inhibitor of N-methyl-D-
aspartate (NMDA) glutamate receptors [33], may also
protect against cerebral ischemia injury by reducing glu-
tamate-mediated glial injury. In addition, it has been
shown that agmatine can rescue astrocytes from death
caused by ischemic and/or ischemia-perfusion neuronal
injury in vitro [34].
Agmatine is stored and synthesized in astrocytes [35].
Arginine decarboxylase, the enzyme responsible for
synthesis of agmatine, is largely localized in astrocytes,
so endogenous agmatine production is likely in astro-
cytes. Abe et al. [36] have reported that agmatine works
to protect neurons by inhibiting the production of nitric
oxide in microglia. During the initial phase of ischemia,
enhanced nitric oxide generated by endothelial nitric
oxide synthase (eNOS) maintains cerebral blood flow,
while nitric oxide generated from neuronal nitric oxide
synthase (nNOS) is neurotoxic [37,38]. Like nNOS, the
induction of inducible nitric oxide synthase (iNOS) can
participate in neuronal damage occurring in the late
phase of focal cerebral ischemia [6,7]. Prior studies have
shown that agmatine reduces the production of nitric
oxide and the expression of nNOS but not iNOS in
vitro. However, in vivo, agmatine inhibites the expres-
sion of both nNOS and iNOS in a mouse model of tran-
sient focal cerebra ischemia [29]. In vitro study has also
demonstrated that agmatine inhibits the production of
nitric oxide by decreasing the activity of iNOS in astro-
glial cells [39]. In the current study, in a rat model of
transient cerebral ischemia, we further show that agma-
tine inhibits the overexpression of cerebral iNOS after
MCAO. These observations prompted us to think that
overproduction of NO from eNOS protects brain tissue
by maintaining regional cerebral blood flow; however,
NO production from either nNOs or iNOS leads to
neurotoxicity. Thereafter, agmatine may reduce cerebral
ischemia injury by inhibiting the detrimental effects of
both iNOS and nNOS.
Similar kind of results were published previously stat-
ing agmatine treatment lowered the expression of iNOS
in the early post ischemic MCAO mice and agmatine
Figure 6 Overexpression of cerebral iNOS by MCAO in rats (n = 8 in each group of different treatments). *The numbers of iNOS-positive
cells (B) 4 days after MCAO injury was significantly (P < 0.05) increased for MCAO-injured animals treated with an i.v. dose of normal saline (1
mL/kg) compared with MCAO sham controls. †The increased numbers of iNOS-positive cells 4 days after MCAO-injury was significantly decreased
for MCAO-injured animals treated with an i.v. dose of agmatine (100 mg/kg) compared with vehicle controls. The photomicrograph (A) illustrates
a typical example for a sham-operated control, a vehicle-treated MCAO rat, and an agmatine-treated MCAO rat.
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had no effect at the later period of reperfusion [15].
These findings are not supported by both previous
[2,39] and present results showing a significant less
expressing of iNOS in agmatine treatment group at the
later period of reperfusion. The reason for the discre-
pancy between the two groups of data are not apparent
now.
Finally, it should be mentioned that AQP4 phosphory-
lation is related to nitric oxide in astrocyte [40]. It is
possible that agmatine would reduce the AQP4
expression in astrocyte by inhibiting nitric oxide
synthase [41,42].
Conclusions
In summary, our current findings revealed that agmatine
therapy reduced cerebral infarct volume by 87%, brain
edema formation by 50% and functional deficits by 70%
4 days after transient cerebral ischemia in the rat. In
addition, both cerebral gliosis (evidenced by overexpres-
sion of both GFAP and AQP4) and neuronal apoptosis
Figure 7 Neuronal apoptosis by MCAO in rats (n = 8 in each group of different treatments). *The numbers of neuronal apoptosis cells (B)
4 days after MCAO injury was significantly (P < 0.05) increased for MCAO-injured animals treated with an i.v. dose of normal saline (1 mL/kg)
compared with MCAO sham control. †The increased numbers of neuronal apoptosis cells 4 days after MCAO injury was significantly decreased
for MCAO-injured animals treated with an i.v. dose of agmatine (100 mg/kg) compared with vehicle controls. The photomicrographs (A)
illustrates a typical example for a sham-operated control, a vehicle-treated MCAO rat, and an agmatine-treated MCAO rat. A cell with NeuN-
TUNEL double positive was recognized as a neuronal apoptosis cell.
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(evidenced by increased numbers of NeuN plus TUNEL
double positive cells) and neurotoxicity (evidenced by
increased iNOS expression) that occurred during transi-
ent cerebral ischemia could be greatly attenuated by
agmatine therapy. It is likely that agmatine therapy
improved the neurological outcome after transient cere-
bral ischemia by reducing neuronal apoptosis, gliosis,
neurotoxicity and cerebral edema formation in the rat.
Key messages
• An intraperitoneal injection of agmatine attenuates
MCAO-induced motor deficits and proprioception
blockade.
• Agmatine therapy attenuates MCAO-induced cere-
bral infarction, edema, gliosis, and neuronal
apoptosis.
• Agmatine therapy attenuates MCAO-induced over-
expression of brain iNOS and AQP4.
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